TriviumVet represented by Susan Kennedy at the information day for SMEs in the veterinary medicines sector organised by European Medicines Agency.

Susan presented TriviumVet’s experience of receiving scientific advice from the EMA. The event gave attendees the opportunity to hear first-hand experience of SME’s and marketing authorisation applications and provided information on the benefits from early dialogue and continuous interaction with EMA during development of innovative veterinary medicines.

TriviumVet work with Texas A&M University on a clinical trial evaluating a new drug – RapaVet® – to treat dilated cardiomyopathy in dogs.

TriviumVet are delighted to be working with Texas A&M University on this exciting clinical trial. Press Release by Texas A&M University: Dilated cardiomyopathy (DCM) is the second most-common acquired cardiac disease in dogs. In its early stage, called the preclinical stage, dogs are apparently healthy to their owners, but beneath the surface, DCM causes a […]

IHS Markit feature: TriviumVet gearing up for pet pipeline launches to bridge therapeutic gaps

TriviumVet_gearing_up_for_pet_pipeline_launches_to_bridge_therapeutic_gaps In case you missed it the first time around you can read the FULL ARTICLE here where IHS Markit’s Sian Lazell caught up with TriviumVet CEO Louise Grubb Ireland’s TriviumVet is a therapeutics and diagnostics start-up targeting a range of unmet needs in companion animal health. Having weathered the COVID-19 pandemic, the company is now […]

FDA’s Center for Veterinary Medicine deems TriviumVet’s feline HCM program eligible for expanded conditional approval pathway

TriviumVet™ are delighted to announce that the Food and Drug Administration’s Center for Veterinary Medicine has determined that our feline hypertrophic cardiomyopathy (HCM) therapeutic candidate, Felycin™ can pursue the expanded conditional approval pathway. US Congress granted the FDA a limited expansion of the conditional approval pathway for certain new animal drugs under the 2018 reauthorization […]

TriviumVet announce collaboration with the Dog Aging Project

TriviumVet, today announced an exciting research collaboration with the Dog Aging Project, TRIAD Trial. What is the Dog Aging Project? The Dog Aging Project is an innovative initiative based in the United States that brings together a community of dogs, owners, veterinarians, researchers, and volunteers to carry out the most ambitious canine health study in […]

TriviumVet announce publication of recent research into gastric acid suppression in dogs

TriviumVet are delighted to announce the publication of a clinical study assessing our first product in development, a gastric acid suppressant to treat gastric ulceration in dogs. Unmet treatment need Worldwide there are no veterinary registered pharmaceutical treatments for gastric ulceration in dogs. Gastric ulceration is a well-recognized disorder in canine veterinary practice, often arising […]

TriviumVet advance their first feline product, a potential treatment for HCM in cats

TriviumVet commence clinical study of first-in-disease treatment for HCM in cats We are delighted to announce the initiation of a ground-breaking clinical study in client-owned cats to evaluate the effectiveness of our patented delayed-release rapamycin formulation (TRIV-203F) in treating hypertrophic cardiomyopathy (HCM). Rapamycin background Results of previous laboratory animal studies and effects observed in human […]